Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05672524 2026-03-04

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Phase 2 Recruiting

37 enrolled

Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms, Meningeal Neoplasms

NCT07193394 2026-02-23

H3RAKLES

Phase 2 Recruiting

20 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02693535 2026-02-13

TAPUR

Phase 2 Recruiting

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT05062889 2026-02-03

ERASE-CRC

Phase 2 Suspended

477 enrolled

Gastrointestinal

Colonic Neoplasms

NCT05583110 2025-12-10

TrasTUCAN

Phase 2 Terminated

13 enrolled

Breast

Breast Neoplasms

NCT05041842 2025-11-17

InTTercePT

Phase 2 Active not recruiting

53 enrolled

Breast

Metastatic Breast Cancer With a Isolated Brain Progression

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Phase 2 Terminated

17 enrolled 16 charts

Breast

Breast Neoplasms, Meningeal Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Phase 2 Recruiting

72 enrolled

Breast

Breast Neoplasms

NCT05955170 2025-03-27

TUC-TOC

Phase 2 Recruiting

66 enrolled

Breast

HER2-positive Breast Cancer

NCT05748834 2025-01-31

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Phase 2 Recruiting

36 enrolled

Breast

Breast Neoplasms

NCT05356897 2024-09-19

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05227131 2022-07-11

MARGARET

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Phase 2 Unknown

120 enrolled

CNS

Brain Neoplasms

Clinical Trials

I-SPY

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

H3RAKLES

TAPUR

ERASE-CRC

TrasTUCAN

InTTercePT

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

TUC-TOC

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

MARGARET

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)